16:03 , Apr 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting CDC25A, CDC25B and CDC25C could help treat breast cancer. In breast cancer patients, high tumor levels of CDC25A, CDC25B and CDC25C correlated with...
08:00 , Nov 13, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms CD8+ T cells that express phosphopeptide-targeted T cell receptor (TCR) to treat cancer Mouse studies suggest CD8+ T cells expressing TCRs that engage with phosphopeptide...
07:00 , Aug 29, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Cyclic adenosine monophosphate (cAMP); cell division cycle 25B (CDC25B); melanocortin 1 receptor (MC1R) Cell culture studies suggest targeting the MC1R-cAMP-CDC25B...
07:00 , Oct 16, 2006 |  BioCentury  |  Tools & Techniques

Understanding the translation

The idea of tumor-specific antigens is hardly new, but much of the work has focused on the expression of a mutant gene that produces a mutant protein, which then serves as an epitope. Another approach...
08:00 , Dec 15, 1997 |  BC Week In Review  |  Clinical News

Mitotix regulatory update

Five U.S. Patents related to cell cycle regulation issued either to the company or to entities from which the company has exclusive licenses. No. 5,672,508, issued to Mitotix, claims nucleic acids that encode peptide fusions...
07:00 , Sep 18, 1995 |  BC Week In Review  |  Company News

Mitotix other research news

The Cambridge, Mass., company and collaborators published the discovery that CDC25 phosphatase enzymes can serve as oncogenes. As reported in Science, high levels of the enzymes keep cell division going. The enzymes normally serve to...
07:00 , Aug 28, 1995 |  BC Week In Review  |  Clinical News

Mitotix regulatory update

Mitotix received U.S. Patent Nos. 5,441,880 and 4,443,962. The '880 patent, to which Mitotix has an exclusive worldwide license, issued to the Cold Spring Harbor Laboratory and covers human and recombinant versions of the proteins...